EVO

Evotec SE [EVO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

EVO Stock Summary

Earnings have grown 21.59% per last year.

The Moving Average Convergence Divergence (MACD) for EVO recently turned positive (within last 10 days).

In the News

EVO Financial details

Company Rating

Market Cap

2.58B

Income

-95.5M

Revenue

799.16M

Book val./share

Cash/share

Dividend

Dividend %

Employees

5.09K

Optionable

Shortable

Yes

Earnings

24 Apr 2024

P/E

-24.62

Forward P/E

PEG

1.74

P/S

4.05

P/B

2.77

P/C

P/FCF

-19.43

Quick Ratio

1.93

Current Ratio

2.16

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.54

EPS next Y

EPS next Q

EPS this Y

-176.15%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

14.89%

Revenue Q/Q

15.27%

EPS Q/Q

160.66%

SMA20

SMA50

33.33%

SMA100

Inst Own

Inst Trans

ROA

-6%

ROE

-15%

ROC

-0.01%

Gross Margin

25%

Oper. Margin

-3%

Profit Margin

-16%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

6.83-13.49

52W High

-68.31%

52W Low

-31.33%

RSI

Rel Volume

6.23

Avg Volume

60.63K

Volume

377.47K

Perf Week

1.73%

Perf Month

-1.2%

Perf Quarter

-7.83%

Perf Half Y

-8.24%

Beta

1.105

Volatility

0.11%, 0.18%

Prev Close

-3.51%

Price

4.12

Change

-3.06%

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 60.63K
Market Capitalization 2.58B
Employee 5.09K
CEO Dr. Mario Polywka DPHIL, Ph.D.
Headquarters Hamburg,DE
IPO Date 2004-02-05
Website https://www.evotec.com

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.